Loading...

Polyphor AG

POLN.SW•SIX
Healthcare
Biotechnology
CHF1.67
CHF-0.12(-6.91%)
empty-state-iconFinancials data is not available for this stockFinancials details for this stock are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Over the last four quarters, Polyphor AG's revenue moved from $1.64M in Q2 2018 to $2510.00 in Q2 2019. Operating income in Q2 2019 was -$16.01M, with a strong operating margin of -637861%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Polyphor AG remained robust at -$15.43M, reflecting operational efficiency. Net income rose to -$16.33M, with an EPS of -$1.48. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;